Please assess the completion status of the following clinical trial:

Trial Title: Plaque REgression With Cholesterol Absorption Inhibitor or Synthesis Inhibitor Evaluated by IntraVascular UltraSound

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Signed written informed consent,~* 30 to 85 years old,~* Plan to undergo PCI and LDL-C \>= 100 mg/dL~Exclusion Criteria:~* Familial hypercholesterolemia~* Being treated with Zetia (Ezetimibe)~* Being treated with Fibrates~* Renal insufficiency (serum creatinine \>= 2.0 mg/dl)~* Altered hepatic function (serum aspartate aminotransferase or alanine aminotransferase \>= 3-folds of standard value in each institute)~* Undergoing hemodialysis or peritoneal dialysis~* Allergic to Lipitor and/or Zetia~* Severe underlying disease~* Lack of decision-making capacity~* Recognized as inadequate by attending doctor

- Gender: ALL
- Minimum Age: 30 Years
- Maximum Age: 85 Years
- Healthy Volunteers: f

Study Arms:
- LZ group (Type: EXPERIMENTAL): None
- L group (Type: ACTIVE_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).